Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: A systematic review

Chest

Volumn 139, Issue 1, 2011, Pages 28-35

  Rodrigo, Gustavo J ^a   Neffen, Hugo ^b   Castro Rodriguez, José A ^c  

^a HOSPITAL CENTRAL DE LAS FUERZAS ARMADAS   (Uruguay)

^b 'O Alassia' Children's Hospital   (Argentina)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; OMALIZUMAB; PLACEBO;

ADD ON THERAPY; AGE; ALLERGIC ASTHMA; ANAPHYLAXIS; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEART ARREST; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LUNG FUNCTION; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URTICARIA;

EID: 78649673636     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-1194     Document Type: Article

References (32)

1. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995;107(1-3):308- 312.
2. Barnes PJ. Anti-IgE therapy in asthma: rationale and therapeutic potential. Int Arch Allergy Immunol. 2000;123(3):196-204.
3. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5)(Suppl):S94-S138.
4. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention: Revised 2009. http://www.ginasthma.com. Accessed April 8, 2010.
5. Tough SC, Hessel PA, Ruff M, Green FH, Mitchell I, Butt JC. Features that distinguish those who die from asthma from community controls with asthma. J Asthma. 1998;35(8):657-665. (Pubitemid 29015373)
6. Turner MO, Noertjojo K, Vedal S, Bai T, Crump S, Fitzgerald JM. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1804-1809. (Pubitemid 28311262)
7. Wenzel SE, Busse WW; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Severe asthma: lessons from the severe asthma research program. J Allergy Clin Immunol. 2007;119(1):14-21., quiz 22-23.
8. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;(2) CD003559.
9. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39(6):788-797.
10. Xolair [omalizumab] full prescribing information. July 2008. http://www.xolair.com/prescribing-information.html. Accessed March 29, 2010.
11. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216.
12. Ohta K, Miyamoto T, Amagasaki T, Yamamoto M; 1304 Study Group. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology. 2009;14(8):1156-1165.
13. European Medicines Agency. Assessment report for Xolair. http://www.ema.europa.eu/humandocs/PDFs/EPAR/Xolair/Xolair-H-606-II-18-AR.pdf. Accessed March 26, 2010.
14. Federal Drug Administration advisory for omalizumab. http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm172218.htm. Accessed January 8, 2010.
15. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical safety data management: definitions and standards for expedited reporting. http://www.ich.org/LOB/media/ MEDIA436.pdf. Accessed January 10, 2010.
16. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-W94.
17. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. www.york.ac.uk/inst/crd/systematic- reviews-book.htm. Accessed January 4, 2010.
18. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
19. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions, version 5.0.0 (updated February 2008). The Cochrane Collaboration; 2008. http://www.cochranehandbook.org. Accessed January 5, 2010.
20. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-analysis. Chichester, England: John Wiley & Songs, Ltd; 2009.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. (Pubitemid 27387172)
22. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219.
23. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.
24. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36.
25. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254-261.
26. Holgate ST, Chuchalin AG, Hébert J, et al; Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34(4):632-638.
27. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709-717.
28. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309-316.
29. Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J. 1999;14(1):23-27.
30. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47(1):81-87.
31. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol. 2007;120(6):1378-1381.
32. American Thoracic Society. 104th International Conference. San Diego, CA. 2009. Abstracts. Publication page: A613. http://www.abstracts2view.com/ats08/ view.php?nu 5 ATS08L-1129. Accessed January 25, 2010.